Table 3.
Univariable and multivariable analysis of progression-free survival in all patients (n = 102).
| Variable | Categorization | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95%CI) | P-value | Hazard ratio (95%CI) | P-value | ||
| Treatment | pembrolizumab vs. bevacizumab | 1.006 (0.604-1.676) | 0.982 | ||
| Age | ≥65 vs. <65 years | 1.747 (1.060-2.879) | 0.029 | 1.315 (0.742-2.329) | 0.348 |
| Sex | male vs. female | 1.150 (0.644-2.053) | 0.637 | ||
| Smoking history | yes vs. no | 1.153 (0.702-1.894) | 0.573 | ||
| ECOG PS | 1 vs. 0 | 0.596 (0.184-1.933) | 0.389 | ||
| Tumor histology | others vs. adenocarcinoma | 3.623 (0.842-15.625) | 0.087 | 3.508 (0.696-17.851) | 0.128 |
| Stage | IV vs. III | 1.817 (0.825-4.001) | 0.138 | ||
| Bone metastases | yes vs. no | 1.966 (1.174-3.291) | 0.010 | 1.590 (0.879-2.874) | 0.125 |
| Brain metastases | yes vs. no | 1.587 (0.844-2.984) | 0.152 | ||
| Liver metastases | yes vs. no | 0.655 (0.237-1.808) | 0.414 | ||
| Chest metastases | yes vs. no | 1.289 (0.722-2.302) | 0.390 | ||
| Adrenal gland metastases | yes vs. no | 1.278 (0.703-2.325) | 0.421 | ||
| LDH | >300 vs. ≤300 U/L | 2.819 (1.374-5.782) | 0.005 | 2.034 (0.900-4.595) | 0.088 |
| NLR | >4.52 vs. ≤4.52 | 2.108 (1.219-3.646) | 0.008 | 1.323 (0.442-3.960) | 0.617 |
| dNLR | >2.70 vs. ≤2.70 | 1.757 (0.978-3.156) | 0.060 | 0.698 (0.257-1.895) | 0.480 |
| PLR | >118.34 vs. ≤118.34 | 1.273 (0.760-2.135) | 0.359 | ||
| LMR | >1.95 vs. ≤1.95 | 0.353 (0.193-0.643) | 0.001 | 0.312 (0.171-0.570) | <0.001 |
| AEC | >0.19 vs. ≤0.19 ×109/L | 0.701 (0.416-1.180) | 0.181 | ||
| Radiotherapy combination | yes vs. no | 1.354 (0.701-2.614) | 0.367 | ||
ECOG PS, Eastern Cooperative Oncology Group performance-status; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; AEC, absolute eosinophil count. Statistically significant values are bolded.